A systematic review of randomised controlled trials in rheumatoid arthritis: The reporting and handling of missing data in composite outcomes

Trials

Volumn 17, Issue 1, 2016, Pages

  Ibrahim, Fowzia ^a   Tom, Brian D M ^b   Scott, David L ^a   Prevost, Andrew Toby ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Composite outcomes; Imputation; Missing data; RA; Sensitivity analysis

Indexed keywords

AMERICAN COLLEGE OF RHEUMATOLOGY; ARTICLE; CLINICAL STUDY; DAS28; HUMAN; INFORMATION PROCESSING; INTENTION TO TREAT ANALYSIS; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PATIENT DROPOUT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; MEASUREMENT ACCURACY; METHODOLOGY; PROCEDURES; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ARTHRITIS, RHEUMATOID; DATA ACCURACY; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; HUMANS; INTENTION TO TREAT ANALYSIS; MODELS, STATISTICAL; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84971441818     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1402-5     Document Type: Article

References (33)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-108. doi: 10.1016/s0140-6736(10)60826-4.
2. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729-40.
3. Felson DT, Anderson JJ, Meenan RF. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum. 1990;33(1):140-9.
4. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-35.
6. Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, et al. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical trials (London, England). 2010;7(1):19-35. doi: 10.1177/1740774509356117.
7. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (Clinical research ed). 2007;334(7597):786.
8. Cohn JN, Tognoni G. Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. doi: 10.1056/NEJMoa010713.
9. Quan H, Zhang D, Zhang J, Devlamynck L. Analysis of a binary composite endpoint with missing data in components. Stat Med. 2007;26(26):4703-18. doi: 10.1002/sim.2893.
10. Senn S, Julious S. Measurement in clinical trials: A neglected issue for statisticians? Stat Med. 2009;28(26):3189-209. doi: 10.1002/sim.3603.
11. Carpenter JR, Kenward MG. Missing data in randomised controlled trials-a practical guide. Birmingham: National Institute for Health Research, Publication RM03/JH17/MK. 2008. http://www.pcpoh.bham.ac.uk/publichealth/methodology/projects/RM03_JH17_MK.shtml. Accessed 30 Apr 2015.
12. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clin Res Ed). 1999;319(7211):670-4.
13. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials. 2004;1(4):368-76.
14. Murphy JF. Consort 2010 statement on randomised controlled trials. Ir Med J. 2010;103(5):132.
15. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clin Res Ed). 2010;340:c332. doi: 10.1136/bmj.c332.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9. W64.
17. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43-50. doi: 10.1136/annrheumdis-2011-201282.
18. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-23. doi: 10.1136/ard.2008.092932.
19. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198-205. doi: 10.1136/ard.2010.148700.
20. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97. doi: 10.1016/s0140-6736(08)60453-5.
21. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804. doi: 10.1136/ard.2008.101659.
22. Weinblatt ME, Bingham 3rd CO, Mendelsohn AM, Kim L, Mack M, Lu J, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013;72(3):381-9. doi: 10.1136/annrheumdis-2012-201411.
23. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64(9):2824-35. doi: 10.1002/art.34498.
24. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-82. doi: 10.1016/s0140-6736(08)61000-4.
25. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541-50.
26. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559-70. doi: 10.1002/art.37816.
27. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat analysis. Clin Trials. 2012;9(4):396-407. doi: 10.1177/1740774512450098.
28. Thabane L, Mbuagbaw L, Zhang SY, Samaan Z, Marcucci M, Ye CL, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92. doi: 10.1186/1471-2288-13-92.
29. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-60. doi: 10.1056/NEJMsr1203730.
30. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther. 2012;91(3):550-4. doi: 10.1038/clpt.2011.340.
31. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ (Clin Res Ed). 2011;342:d40. doi: 10.1136/bmj.d40.
32. Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ. Trial attrition study group. Assessing the impact of attrition in randomized controlled trials. J Clin Epidemiol. 2010;63(11):1264-70. doi: 10.1016/j.jclinepi.2010.01.010.
33. Baron G, Boutron I, Giraudeau B, Ravaud P. Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. Arthritis Rheum. 2005;52(6):1858-65. doi: 10.1002/art.21116.